Yi-Wei Tang

Dr. Yi-Wei Tang

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
HLHongzhou Lu
Hongzhou Lu
CSCharles W. Stratton
Charles W. Stratton
Yi-Wei TangYi-Wei Tang
Yi-Wei Tang

26 May 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
Yi-Wei TangYi-Wei Tang
Yi-Wei Tang
JSJonathan E. Schmitz
Jonathan E. Schmitz
DPDavid H. Persing
David H. Persing
CSCharles W. Stratton
Charles W. Stratton
The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the preanalytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results.

1 January 2020 in Emerging Microbes & Infections
Verified
Journal Article
Open access
MLMichael J. Loeffelholz
Michael J. Loeffelholz
Yi-Wei TangYi-Wei Tang
Yi-Wei Tang
The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of 21st century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasal-pharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.

1 July 2017 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ZPZhong Peng
Zhong Peng
DJDazhi Jin
Dazhi Jin
HKHyeun Bum Kim
Hyeun Bum Kim
CSCharles W. Stratton
Charles W. Stratton
BWBin Wu
Bin Wu
XSXingmin Sun
Xingmin Sun
Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies of choice for Clostridium difficile infection. Several important mechanisms for C. difficile antibiotic resistance have been described, including the acquisition of antibiotic resistance genes via the transfer of mobile genetic elements, selective pressure in vivo resulting in gene mutations, altered expression of redox-active proteins, iron metabolism, and DNA repair, as well as via biofilm formation. This update summarizes new information published since 2010 on phenotypic and genotypic resistance mechanisms in C. difficile and addresses susceptibility test methods and other strategies to counter antibiotic resistance of C. difficile .

1 April 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MSMichael Satlin
Michael Satlin
LCLiang Chen
Liang Chen
GPGopi Patel
Gopi Patel
AGAngela Gomez-Simmonds
Angela Gomez-Simmonds
GWGregory Weston
Gregory Weston
BKBarry N. Kreiswirth
Barry N. Kreiswirth
Although the New York/New Jersey (NY/NJ) area is an epicenter for carbapenem-resistant Enterobacteriaceae (CRE), there are few multicenter studies of CRE from this region. We characterized patients with CRE bacteremia in 2013 at eight NY/NJ medical centers and determined the prevalence of carbapenem resistance among Enterobacteriaceae bloodstream isolates and CRE resistance mechanisms, genetic backgrounds, capsular types ( cps ), and antimicrobial susceptibilities. Of 121 patients with CRE bacteremia, 50% had cancer or had undergone transplantation. The prevalences of carbapenem resistance among Klebsiella pneumoniae , Enterobacter spp., and Escherichia coli bacteremias were 9.7%, 2.2%, and 0.1%, respectively. Ninety percent of CRE were K. pneumoniae and 92% produced K. pneumoniae carbapenemase (KPC-3, 48%; KPC-2, 44%). Two CRE produced NDM-1 and OXA-48 carbapenemases. Sequence type 258 (ST258) predominated among KPC-producing K. pneumoniae (KPC- Kp ). The wzi154 allele, corresponding to cps-2 , was present in 93% of KPC-3- Kp , whereas KPC-2- Kp had greater cps diversity. Ninety-nine percent of CRE were ceftazidime-avibactam (CAZ-AVI)-susceptible, although 42% of KPC-3- Kp had an CAZ-AVI MIC of ≥4/4 μg/ml. There was a median of 47 h from bacteremia onset until active antimicrobial therapy, 38% of patients had septic shock, and 49% died within 30 days. KPC-3- Kp bacteremia (adjusted odds ratio [aOR], 2.58; P = 0.045), cancer (aOR, 3.61, P = 0.01), and bacteremia onset in the intensive care unit (aOR, 3.79; P = 0.03) were independently associated with mortality. Active empirical therapy and combination therapy were not associated with survival. Despite a decade of experience with CRE, patients with CRE bacteremia have protracted delays in appropriate therapies and high mortality rates, highlighting the need for rapid diagnostics and evaluation of new therapeutics.

1 June 2015 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
HZHongwei Zhang
Hongwei Zhang
SMScott Morrison
Scott Morrison
Yi-Wei TangYi-Wei Tang
Yi-Wei Tang